Compound description
What is IDRA-21
IDRA-21 (7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide, CAS 22503-72-6) is a first-generation ampakine, a benzothiadiazine derivative and congener of aniracetam. Developed in the 1990s by the group of Erminio Costa and Alessandro Guidotti at the University of Illinois at Chicago, together with the Italian company Cortecs/Cortex Pharmaceuticals. It is a historical benchmark among AMPA-PAMs, from which later, more potent ampakines were developed — CX-516, CX-717, and eventually TAK-653.
Mechanism. AMPA receptors (GluA1–GluA4 subunits) mediate fast excitatory synaptic transmission but rapidly desensitize — temporarily failing to respond even in the continued presence of agonist. IDRA-21, a cyclothiazide analogue, inhibits this desensitization and deactivation: the receptor stays open longer, prolonging the excitatory postsynaptic current, which facilitates long-term potentiation (LTP). IDRA-21 does not activate the receptor on its own — it is a modulator, not an agonist, and requires endogenous glutamate to act. Unlike cyclothiazide, it crosses the blood-brain barrier much more readily and is active orally.
Potency relative to aniracetam. Both compounds attenuate AMPA receptor desensitization, but IDRA-21 is 10–30 times more potent than aniracetam at reversing cognitive deficits induced by alprazolam or scopolamine.
Discovery and first characterization. Zivkovic et al. (1995, J Pharmacol Exp Ther) first described the compound in detail: the mechanism of attenuated AMPA receptor desensitization, improved spatial memory in a water maze in normal rats, and the ability to reverse amnesia induced by alprazolam and scopolamine.
Primate studies. Thompson et al. (1995, PNAS) showed in patas monkeys that IDRA-21 (3 or 5.6 mg/kg orally) and aniracetam (30 mg/kg), while having no effect on behavior on their own, significantly attenuated alprazolam-induced learning impairment in a complex behavioral task. Later, in rhesus monkeys performing a delayed matching-to-sample (DMTS) task, a single dose improved accuracy in aged animals by roughly 18%, with the effect lasting up to 48 hours (Buccafusco et al., 2004).
Safety profile. At cognitively effective doses, IDRA-21 produces virtually none of the neurotoxicity or seizures associated with direct AMPA agonists. Impagnatiello et al. (1997) showed an absence of neurotoxicity unlike cyclothiazide; Losi et al. (2004) confirmed that doses effective for cognition in rats and monkeys are orders of magnitude below those causing neurotoxicity in cell culture.
An important caveat. A separate study (Yamada et al., 1998) showed the opposite effect in a different context — IDRA-21 worsened hippocampal neuronal damage in an ischemia model. This does not contradict the safety data under normal conditions, but it does mean the compound's effects are context-dependent: the conclusion "no neurotoxicity under normal function" cannot be extrapolated to states of acute cerebral oxygen deprivation.
Effects in rodents. Orally active at doses of 0.15–10 mg/kg: improves spatial memory and learning, enhances hippocampal LTP, and facilitates glutamatergic transmission via GluA1/GluA2 — with effects seen not only in models of pharmacologically impaired memory but also in normal animals.
